Development and validation of a questionnaire for measuring  drug-induced nausea

Andjelka  Prokić; Slobodan M. Janković

doi:10.2298/VSP170421123P

Andjelka Prokić University of Kragujevac, Faculty of Medical Sciences, Department of Pharmacology and Toxicology, Kragujevac, Serbia
Slobodan M. Janković University of Kragujevac, Faculty of Medical Sciences, Department of Pharmacology and Toxicology, Kragujevac, Serbia

DOI: https://doi.org/10.2298/VSP170421123P

Keywords: drug therapy;, iron;, nausea;, pharmaceutical preparations;, psychometrics;, surveys and questionnaires.

Abstract

Background/Aim. There are several questionnaires for measuring intensity of nausea after drug administration, but they are either too settings specific (like those measuring chemotherapy-induced nausea), or they were not properly tested for reliability and validity. The aim of this study was to develop and validate a reliable instrument that can measure drug-induced nausea. Methods. The cross-sectional study for assessing reliability and validity of a questionnaire was performed. The questionnaire with 5 items and answers according to the Likert’s scale was developed during two brainstorming sessions of the research team. Its reliability, validity and temporal stability were tested on the sample of 128 outpatients taking iron salts orally. Results. The final version of the Drug-Induced Nausea Scale (DINS) with 5 items showed excellent reliability, both when rated by the investigators (Cronbach’s alpha 0.892) and by the patients themselves (Cronbach’s alpha 0.897). It was temporally stable, and both divergent and convergent validity tests had very good results. Factorial analysis revealed only one factor, which means that the whole scale is measuring only one phenomenon, intensity of nausea, as was originally intended. Conclusion. The DINS is reliable and valid instrument for measuring intensity of drug-induced nausea. Identification of patients with high intensity of drug-induced nausea by this questionnaire will help prescribers to decide whether the therapy should be stopped or the patient switched to less emetogenic therapy.

References

Hendren G, Aponte-Feliciano A, Kovac A. Safety and efficacy of commonly used antiemetics. Expert Opin Drug MetabToxicol 2015; 11(11): 1753–67.

Turini M, Piovesana V, Ruffo P, Ripellino C, Cataldo N. An as-sessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries. Drugs Context 2015; 4: 212285.

Leppert W. Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction. Drug Des Devel Ther 2015; 9: 2215–31.

Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One 2015; 10(2): e0117383.

Geisser P, Burckhardt S. The pharmacokinetics and pharmaco-dynamics of iron preparations. Pharmaceutics 2011; 3(1): 12–33.

Martin CG, Rubenstein EB, Elting LS, Kim YJ, Osoba D. Meas-uring chemotherapy‐induced nausea and emesis. Cancer 2003; 98(3): 645–55.

Pereira DI, Couto Irving SS, Lomer MC, Powell JJ. A rapid, sim-plequestionnaire to assess gastrointestinal symptoms after oral ferrous sulphate supplementation. BMC Gastroenterol 2014; 14: 103.

Spiegel BM, Hays RD, Bolus R, Melmed GY, Chang L, Whitman C, et al. Development of the NIH Patient-Reported Out-comes Measurement Information System (PROMIS) gastroin-testinal symptom scales. Am J Gastroenterol 2014; 109(11): 1804-14.

DeVellis RF. Scale Development, Theory and Applications. 2nd ed. Newbury Park: SAGE Publications; 2003.

Morrow GR, Navari RM, Rugo HS. Clinical roundtable mono-graph: new data in emerging treatment options for chemother-apy-induced nausea and vomiting. Clin Adv Hematol Oncol 2014; 12(3 Suppl 9): 1–14; quiz 15.

Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, et al. ISPOR Task Force for Translation and Cul-tural Adaptation. Principles of Good Practice for the Transla-tion and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health 2005; 8(2): 94–104.

Streiner DL, Norman GR. Health Measurement Scales - a prac-tical guide to their development and use. 4st ed. Oxford: Ox-ford University Press; 2008.

Badia X, Arribas F, Ormaetxe JM, Peinado R, de Los Terreros MS. Development of a questionnaire to measure health-related quality of life (HRQoL) in patients with atrial fibrilla-tion (AF-QoL). Health Qual Life Outcomes 2007; (5): 37.

Mihić Lj, Sokić J, Samac N, Ignjatović I. Serbian adaptation and validation of the Intolerance of Uncertainty Scale. Primenjena psihologija 2014; 7(Suppl): 347–70. (Serbian)

Khanna D, Hays RD, Shreiner AB, Melmed GY, Chang L, Khan-na PP, et al. Responsiveness to Change and Minimally Im-portant Differences of the Patient-Reported Outcomes Meas-urement Information System Gastrointestinal Symptoms Scales. Dig Dis Sci 2017; 62(5): 1186–92.

Brearley SG, Clements CV, Molassiotis A. A review of patient self-report tools for chemotherapy-induced nausea and vomit-ing. Support Care Cancer 2008; 16(11): 1213–29.

Phillips RS, Friend AJ, Gibson F, Houghton E, Gopaul S, Craig JV, et al. Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood. Cochrane Database Syst Rev 2016; 2: CD007786.